28 results on '"Pirisi, Mario"'
Search Results
2. Plasma Pattern of Extracellular Vesicles Isolated from Hepatitis C Virus Patients and Their Effects on Human Vascular Endothelial Cells.
- Author
-
Grossini, Elena, Smirne, Carlo, Venkatesan, Sakthipriyan, Tonello, Stelvio, D'Onghia, Davide, Minisini, Rosalba, Cantaluppi, Vincenzo, Sainaghi, Pier Paolo, Comi, Cristoforo, Tanzi, Adele, Bussolati, Benedetta, and Pirisi, Mario
- Subjects
VASCULAR endothelial cells ,HEPATITIS C virus ,EXTRACELLULAR vesicles ,PROTEIN kinase B ,ENDOTHELIUM diseases - Abstract
Hepatitis C virus (HCV) patients are at increased risk of cardiovascular disease (CVD). In this study, we aimed to evaluate the role of extracellular vesicles (EVs) as pathogenic factors for the onset of HCV-related endothelial dysfunction. Sixty-five patients with various stages of HCV-related chronic liver disease were enrolled in this case series. Plasma EVs were characterized and used to stimulate human vascular endothelial cells (HUVEC), which were examined for cell viability, mitochondrial membrane potential, and reactive oxygen species (ROS) release. The results showed that EVs from HCV patients were mainly of endothelial and lymphocyte origin. Moreover, EVs were able to reduce cell viability and mitochondrial membrane potential of HUVEC, while increasing ROS release. Those harmful effects were reduced by the pretreatment of HUVEC with the NLR family pyrin domain containing 3 (NLRP3)/AMP-activated protein kinase and protein kinase B blockers. In conclusion, in HCV patients, we could highlight a circulating pattern of EVs capable of inducing damage to the endothelium. These data represent a novel possible pathogenic mechanism underlying the reported increase of CVD occurrence in HCV infection and could be of clinical relevance also in relation to the widespread use of antiviral drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma
- Author
-
Pinato, David J., Pai, Madhava, Reccia, Isabella, Patel, Markand, Giakoustidis, Alexandros, Karamanakos, Georgios, Rushd, Azelea, Jamshaid, Shiraz, Oldani, Alberto, Grossi, Glenda, Pirisi, Mario, Tait, Paul, and Sharma, Rohini
- Published
- 2018
- Full Text
- View/download PDF
4. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis.
- Author
-
Sacco, Rodolfo, Ramai, Daryl, Tortora, Raffaella, di Costanzo, Giovan Giuseppe, Burlone, Michela Emma, Pirisi, Mario, Federico, Piera, Daniele, Bruno, Silletta, Marianna, Gallo, Paolo, Cocuzza, Caterina, Russello, Maurizio, Cabibbo, Giuseppe, Rancatore, Gabriele, Cesario, Silvia, Masi, Gianluca, Marzi, Luca, Mega, Andrea, Granito, Alessandro, and Pieri, Giulia
- Subjects
THERAPEUTIC use of monoclonal antibodies ,RESEARCH ,CONFIDENCE intervals ,LOG-rank test ,INFLAMMATION ,IMMUNOSUPPRESSION ,CANCER patients ,KAPLAN-Meier estimator ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,FACTOR analysis ,PROGRESSION-free survival ,ODDS ratio ,HEPATOCELLULAR carcinoma ,OVERALL survival - Abstract
Simple Summary: Hepatocellular carcinoma is the fifth most common cancer worldwide. For patients with advanced hepatocellular carcinoma, therapeutic options are limited. Lenvatinib has proven to be an effective option for treating advanced diseases. For patients treated with lenvatinib, our study showed that the etiology of liver disease plays a significant role in overall survival. Patients whose liver disease was driven by nonviral etiologies showed longer survival than viral etiologies. These results are important for clinical decision-making between patients and clinicians. Background: Whether the etiology of underlying liver disease represents a prognostic factor in patients with hepatocellular carcinoma (HCC) treated with lenvatinib is still a matter of debate. This study investigates whether the viral etiology of HCC plays a prognostic role in overall survival (OS). Methods: Data derived from a multicenter series of 313 HCC patients treated with lenvatinib between 2019 and 2022 were analyzed. Actuarial survival estimates were computed using the Kaplan–Meier method and compared with the log-rank test. We performed an event-based counterfactual mediation analysis to estimate direct (chronic inflammation and immunosuppression), indirect (tobacco smoking, alcohol use, illicit drug abuse with injections), and the total effect of viral etiology on OS. Results were expressed as hazard ratio (HR) and 95% CI. Results: Median OS was 21 months (95% CI: 20–23) in the group with other etiologies and 15 months (14–16) in the group with viral etiology (p < 0.0001). The total effect of viral etiology was associated with OS (HR 2.76, 1.32–5.21), and it was mainly explained by the pure direct effect of viral etiology (HR 2.74, 1.15–4.45). By contrast, its total indirect effect was not associated with poorer survival (HR 1.05, 0.82–2.13). These results were confirmed when considering tobacco, alcohol consumption, or injection drug abuse as potential mediators. Median progression-free survival was 9 months (8–10) in patients with other etiologies and 6 months (5–7) in patients with viral etiology (p < 0.0001). No difference in terms of adverse event rate was observed between the two groups. Conclusions: Patients affected by HCC with nonviral etiology treated with lenvatinib exhibit longer survival than those with viral etiology. This finding may have relevance in the treatment decision-making process. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development.
- Author
-
Caviglia, Gian Paolo, Abate, Maria Lorena, Troshina, Giulia, Carucci, Patrizia, Rolle, Emanuela, Risso, Alessandra, Burlone, Michela Emma, Albè, Alice, Crevola, Martina, Musso, Emma Clara, Rosso, Chiara, Armandi, Angelo, Olivero, Antonella, Minisini, Rosalba, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Pirisi, Mario, Ciancio, Alessia, and Gaia, Silvia
- Subjects
CHEMILUMINESCENCE immunoassay ,HEPATOCELLULAR carcinoma ,DIAGNOSTIC ultrasonic imaging ,TUMOR markers ,VITAMIN K ,CIRRHOSIS of the liver - Abstract
Simple Summary: The use of tumor biomarkers, although debated, for the surveillance of patients at risk of HCC, is common practice in many clinical centers. Here, we investigated the best cut-off value for one of such biomarkers, protein induced by vitamin K absence, or antagonist-II in a large cohort of patients with liver cirrhosis under surveillance. We observed that a cut-off value of 50 mAU/mL was appropriate for the discrimination between patients with hepatocellular carcinoma and those without tumor, and among the latter, allowed the identification of patients with an increased risk of developing hepatocellular carcinoma during the follow-up. Patients with cirrhosis are at risk of hepatocellular carcinoma (HCC) development and, according to current guidelines, should undergo surveillance by ultrasound at six month intervals. Due to the known limitations of surveillance strategies based on ultrasonography, the use of tumor biomarkers, although debated, is common practice in many centers. The aim of the study was to identify the best cut-off value for one of such biomarkers, protein induced by vitamin K absence, or antagonist-II (PIVKA-II). We retrospectively enrolled 1187 patients with liver cirrhosis: 205 with a diagnosis of HCC (median age 67 years, 81.0% males) and 982 without tumor (median age 64 years, 56.2% males). During a median follow-up (FU) of 34.6 (11.4–43.7) months, 118 out of 982 (12.0%) patients developed HCC. Serum PIVKA-II was assessed by chemiluminescence immunoassay on the Lumipulse
® G600 II platform (Fujirebio, Tokyo, Japan). In the overall cohort (n = 1187), PIVKA-II showed an area under the curve (AUC) of 0.802 for HCC detection. The best cut-off value that maximized sensitivity was 50 mAU/mL (sensitivity = 80%, specificity = 64%). In the 982 patients without HCC at baseline, PIVKA-II > 50 mAU/mL was associated with an increased risk of HCC development during the FU (HR = 1.74, 95% CI 1.21–2.51; p = 0.003)). In conclusion, the evaluation of serum PIVKA-II showed a good performance for HCC detection; a cut-off value > 50 mAU/mL could be suitable for the surveillance of patients who are at risk of developing HCC. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study
- Author
-
Pirisi, Mario, Avellini, Claudio, Fabris, Carlo, Scott, Cathryn, Bardus, Paola, Soardo, Giorgio, Beltrami, Carlo A., and Bartoli, Ettore
- Published
- 1998
- Full Text
- View/download PDF
7. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis.
- Author
-
Martelletti, Carolina, Ricotti, Andrea, Gesualdo, Marcantonio, Carucci, Patrizia, Gaia, Silvia, Rolle, Emanuela, Burlone, Michela Emma, Okolicsanyi, Stefano, Mattalia, Alberto, Pirisi, Mario, Berchialla, Paola, and Tabone, Marco
- Subjects
PORTAL vein ,BAYESIAN analysis ,HEPATOCELLULAR carcinoma ,SORAFENIB ,OVERALL survival - Abstract
Objective: In this study we aimed to compare patient outcomes between the use of transarterial radioembolization (TARE) and sorafenib in patients with hepatocellular carcinoma (HCC) and intrahepatic portal vein tumor thrombosis (PVTT). Methods: A total of 65 patients with HCC and intrahepatic PVTT treated in five Italian hospitals between 2012 and 2018 were included in the analysis. Those with any previous treatment, extension of PVTT to the main portal tract and extrahepatic involvement were excluded. Propensity score matching analysis and Bayesian model averaging analysis were performed. Results: Of the 41 patients treated with TARE and 24 with sorafenib, 11 patients were downstaged to curative‐intent surgery (liver transplant in three and hepatectomy in eight), including 10 treated with TARE and one with sorafenib. TARE was more effective than sorafenib in downstaging patients to surgery, achieving a mean survival of 54 months. In the 54 patients without downstaging after treatment, of whom 31 were treated with TARE and 23 with sorafenib, median survival was 20.3 and 9.1 months, respectively (P = 0.001), with different 1‐, 2‐ and 3‐year OS rates (64.5%, 42.6% and 37.3% vs 39.1%, 13.0% and 0%). Both propensity score and Bayesian model averaging confirmed an improvement in overall survival in the TARE group compared with sorafenib treatment. Conclusions: TARE was more effective than sorafenib in downstaging patients with HCC to surgery, providing a significant improvement in survival. Even in patients who were not downstaged to surgery, survival appeared to be superior with TARE over sorafenib. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Circulating intercellular adhesion molecule 1 predicts non-specific elevation of α1-fetoprotein
- Author
-
Falleti, Edmondo, Fabris, Carlo, Pirisi, Mario, Soardo, Giorgio, Vitulli, Daniela, Toniutto, Pierluigi, Bortolotti, Nadia, Gonano, Fabio, and Bartoli, Ettore
- Published
- 1996
- Full Text
- View/download PDF
9. Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis
- Author
-
Fabris, Carlo, Pirisi, Mario, Soardo, Giorgio, Falleti, Edmondo, Pezzetta, Francesca, Vitulli, Daniela, Toniutto, Pierluigi, Bortolotti, Nadia, Gonano, Fabio, and Bartoli, Ettore
- Published
- 1994
- Full Text
- View/download PDF
10. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
- Author
-
Hajiev, Saur, Allara, Elias, Motedayеn Aval, Leila, Arizumi, Tadaaki, Bettinger, Dominik, Pirisi, Mario, Rimassa, Lorenza, Pressiani, Tiziana, Personeni, Nicola, Giordano, Laura, Kudo, Masatoshi, Thimme, Robert, Park, Joong-Won, Taddei, Tamar H., Kaplan, David E., Ramaswami, Ramya, Pinato, David J., and Sharma, Rohini
- Subjects
RESEARCH ,LIVER tumors ,AGE distribution ,RESEARCH methodology ,ANTINEOPLASTIC agents ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,DOSE-effect relationship in pharmacology ,HEPATOCELLULAR carcinoma ,LONGITUDINAL method - Abstract
Background: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly.Methods: In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while accounting for common prognostic factors and demographic characteristics in univariable and multivariable models.Results: Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years. The elderly were more likely to have larger tumours (>7 cm) (39 vs 33%, p < 0.01) with preserved liver function (67 vs 57.7%) (p < 0.01). No difference in the median OS of those aged ≥75 years and <75 was noted (7.3 months vs 7.2 months; HR 1.00 (95% CI 0.93-1.08), p = 0.97). There was no relationship between starting dose of sorafenib 800 mg vs 400 mg/200 mg and OS between those <75 and ≥75 years. The elderly experienced a similar overall incidence of grade 2-4 sorafenib-related toxicity compared to <75 years (63.5 vs 56.7%, p = 0.11). However, the elderly were more likely to discontinue sorafenib due to toxicity (27.0 vs 21.6%, p < 0.01). This did not vary between different starting doses of sorafenib.Conclusions: Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib prescribed. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients.
- Author
-
De Benedittis, Carla, Bellan, Mattia, Crevola, Martina, Boin, Elena, Barbaglia, Matteo Nazzareno, Mallela, Venkata Ramana, Ravanini, Paolo, Ceriani, Elisa, Fangazio, Stefano, Sainaghi, Pier Paolo, Burlone, Michela Emma, Minisini, Rosalba, and Pirisi, Mario
- Subjects
HEPATITIS C ,SINGLE nucleotide polymorphisms ,HEPATOCELLULAR carcinoma ,FATTY liver ,CHRONIC hepatitis C ,DISEASE risk factors - Abstract
A single-nucleotide polymorphism causing a C to G change in the PNPLA3 gene (rs738409) is associated with disease severity and development of hepatocellular carcinoma (HCC) in nonalcoholic fatty liver disease; the insertion variant rs72613567:TA of the 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) mitigates this detrimental effect. Our aim was to evaluate if the same holds true in chronic hepatitis C virus infection (HCV). With a case control retrospective study design, we selected 110 patients who developed HCC on a background of HCV infection, matching each patient for sex and age (±30 months) to three HCV-infected, non-HCC patients. All participants underwent genotyping for PNPLA3 and HSD17B13 gene variants. Both univariate and multivariate analyses of risk factors for advanced disease and HCC were performed. Carriage of PNPLA3 G ∗ allele was associated with a trend of progressively more severe liver disease, from mild fibrosis to significant fibrosis, cirrhosis, and HCC (p = 0.007). When the HSD17B13:TA status of these patients was taken into account, the abovementioned trend was strengthened among HSD17B13 major allele homozygotes and completely blunted among carriers of the minor allele (p = 0.0003 and 0.953, respectively). In a conditional logistic regression model including diabetes and AST to platelet ratio index among predictor variables, the unfavourable genetic profile characterized by the coexistence of the PNPLA3 minor allele and HSD17B13 major allele (vs. all other possible combinations) was an independent risk factor for HCC (OR = 2.00 , 95% CI: 1.23-3.26) together with a history of alcohol abuse. In conclusion, carriage of the combination PNPLA3 minor allele and HSD17B13 major allele may represent a risk factor for HCC among HCV-infected patients. The interplay between the two genes may explain some of the controversy on this topic and may be exploited to stratify HCC risk in hepatitis C. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy.
- Author
-
Stroffolini, Tommaso, Sagnelli, Evangelista, Sagnelli, Caterina, Morisco, Filomena, Babudieri, Sergio, Furlan, Caterina, Pirisi, Mario, Russello, Maurizio, Smedile, Antonina, Pisaturo, Mariantonietta, and Almasio, Piero Luigi
- Subjects
HEPATITIS B ,HEPATITIS C ,HEPATOCELLULAR carcinoma ,CIRRHOSIS of the liver ,DISEASE incidence ,DESCRIPTIVE statistics - Abstract
Background: The epidemiology of hepatocellular carcinoma (HCC) is characterized by a dynamical temporal trend of well-established and emerging risk factors. Methods: We evaluated the temporal trend of aetiological factors of HCC over the last two decades in Italy. HCC cases were recruited from two previously published national studies in 1996 and in 2008 and HCC cases were also enlisted from two national surveys in 2001 and in 2014 enrolling consecutive subjects with chronic liver disease (CLD) referring to more than 80 liver units scattered all over the country for a 6-month period. Results: Out of the 9997 subjects with CLD recruited in 2001 and the 2408 recruited in 2014, 3.3% and 5.7% (P < 0.001), respectively, had HCC. The temporal trend of HBsAg −/HCV + HCC cases significantly linearly decreased from 71.1% in 1996 to 57.2% in 2014 (P < 0.001). Conversely, that of virus-negative cases significantly linearly increased from 12.1% to 28.3% (P < 0.001). The proportion of HBV-related HCC cases showed a steady low rate, reflecting the reduced endemicity of the infection in Italy. The proportion of HCC with compensated cirrhosis (i.e., Child–Pugh A) linearly increased over time from 55.6% in 1996 to 76.0% in 2014 (P < 0.001) reflecting the growing effectiveness of semi-annual ultrasound surveillance for early detection of HCC. Conclusion: In conclusion, with decreasing viral aetiology, an overall decrease in the incidence of HCC might be expected in the future. The proportion of metabolic diseases is conversely increasing being considered as an aetiology. The growing prevalence of metabolic disorders in the general population may further increase this trend in the years to come. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy.
- Author
-
Sagnelli, Evangelista, Stroffolini, Tommaso, Sagnelli, Caterina, Pirisi, Mario, Babudieri, Sergio, Colloredo, Guido, Russello, Maurizio, Coppola, Nicola, Gaeta, Giovanni Battista, Cacopardo, Bruno, De Luca, Massimo, Almasio, Piero Luigi, and on behalf of EPACRON study group
- Subjects
ALCOHOLIC liver diseases ,COMPARATIVE studies ,HEPATITIS C ,CIRRHOSIS of the liver ,LIVER diseases ,LONGITUDINAL method ,SEX distribution ,SURVEYS - Abstract
Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014).Methods: The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods.Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely to show HCV infection alone (48.0% vs. 67.9%). A male preponderance was observed in HBV-related cases (1.99) and in alcoholic-related cases (2.3), a preponderance observed both in the 2001 and in 2014 cases. In HCV-related cases, however, females predominated in 2001 (M/F 0.9) and males in 2014 (M/F 1.5).The rate of cirrhosis in alcohol-related etiology was close to 36% in both genders, a finding much higher than that observed for both sexes in HBV and HCV etiologies.Both males and females enrolled in 2014 were older (
p < 0.001) and with a higher rate of cirrhosis and/or HCC (p < 0.001) than those investigated in 2001. There was a remarkable increase over time in the proportion of male abstainers (36.7% in 2001 and 64.3% in 2014).Conclusion: This study highlights important inter- and intra-gender differences in the characteristics and etiological factors of patients with CLD in Italy. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
- Author
-
Stroffolini, Tommaso, Sagnelli, Evangelista, Andriulli, Angelo, Colloredo, Guido, Furlan, Caterina, Gaeta, Giovanni Battista, Morisco, Filomena, Pirisi, Mario, Rosina, Floriano, Sagnelli, Caterina, Smedile, Antonina, Almasio, Piero Luigi, and null, null
- Subjects
CIRRHOSIS of the liver ,ALCOHOL drinking & health ,HEPATITIS B virus ,HEPATITIS C virus ,SEX factors in disease ,DISEASE risk factors - Abstract
Background: The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective: Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design: We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysis. Results: Females were older than males (p<0.01) and less frequently showed HBV and alcoholic aetiology (p<0.01). In both sexes, an overtime increasing age and an increasing proportion of subjects with liver cirrhosis was observed, reflecting a better survival (0.01). An additive interaction is observed in females: the O.R. generated by the simultaneous presence of HBV, HCV, and alcohol (5.09; 95% C.I. 1.06–24.56) exceeds the sum (4.14) of the O.R. generated by a single exposure (O.R. = 0.72 for HBsAg positivity, OR = 1.34 for anti-HCV positivity, and O.R. = 2.08 for alcohol intake). No interaction is observed in male sex. Conclusions: The observed gender difference suggests that the simultaneous presence of HBV/HCV coinfection and risky alcohol intake enhances the mechanism of liver damage to a greater extent in females than in males. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application.
- Author
-
Pinato, David J., Karamanakos, Georgios, Ishizuka, Mitsuru, Smirne, Carlo, Pirisi, Mario, Kubota, Keiichi, and Sharma, Rohini
- Subjects
LIVER cancer ,CANCER patients ,AMINOTRANSFERASES ,CANCER treatment ,HETEROGENEITY - Abstract
Background & Aims There are a number of prognostic scores in hepatocellular carcinoma ( HCC), none of which is optimal in predicting overall survival ( OS) in the individual patient, particularly in intermediate stage disease, where patients are not surgically treatable but may qualify for a wide range of palliative interventions. We evaluated the prognostic role of a biochemical algorithm, the Kings Score ( KS), in the palliative setting of care. Methods We used the algorithm [age x AST x INR]/platelet count to derive the KS. Full clinical data including Barcelona Clinic Liver Cancer ( BCLC) stage were studied in a training set of 97 patients from the UK. Independent predictors of survival identified in multivariate analysis were validated in an independent cohort of 766 patients from Japan and Italy. Results In both training and validation sets, KS was confirmed as an independent predictor of OS ( P < 0.01). Ad-hoc subgroup analysis revealed the KS to be prognostic in the palliative setting, being able to subclassify patients presenting with intermediate and advanced disease according to BCLC criteria ( P < 0.001). Conclusion The KS integrates into the BCLC system to improve prognostic substratification in the palliative setting of care. The KS may help reducing disease heterogeneity and refine treatment allocation in intermediate-advanced HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.
- Author
-
Falleti, Edmondo, Fabris, Carlo, Cmet, Sara, Cussigh, Annarosa, Bitetto, Davide, Fontanini, Elisabetta, Fornasiere, Ezio, Bignulin, Sara, Fumolo, Elisa, Bignulin, Eleonora, Pirisi, Mario, and Toniutto, Pierluigi
- Subjects
ETIOLOGY of diseases ,CANCER patients ,LIVER cancer ,GENETIC polymorphisms ,ADIPOSE tissues ,MULTIVARIATE analysis ,ITALIANS ,CAUCASIAN race - Abstract
Background and aim: The PNPLA3 rs738409 C>G polymorphism has been found to be strongly associated with non-alcoholic fatty liver disease and with alcoholic liver disease. Whether the PNPLA3 rs738409 polymorphism could be a risk factor for the development of hepatocellular carcinoma (HCC) in cirrhosis patients is unknown. Methods: This study included 483 (344 males) consecutive Italian patients of Caucasian ethnicity affected by cirrhosis, of whom 279 had undergone transplantation for end-stage liver disease while 204 had been referred to our liver and transplant unit for the diagnosis of cirrhosis. The aetiologies were hepatitis C virus=209, hepatitis B virus=76, alcohol=166, metabolic=32. Ile148Met rs738409 transversion was genotyped using an restriction fragment length polymorphism-based assay. Results: The genotype frequencies of the rs738409 polymorphism were distributed differently in patients with cirrhosis C/C=168, C/G=220, G/G=95 vs controls C/C=218, C/G=175, G/G=35 ( P<0.0001). Among cirrhotics, the G allele was over-represented in alcoholic/metabolic (0.505) vs viral (0.368, P<0.001) liver disease. Patients with cirrhosis complicated by HCC were more likely to be G/G homozygotes (38/141) than the remaining patients (57/342, P<0.02). At multivariate analysis, the PNPLA3 rs738409 polymorphism was confirmed to be an independent predictor of HCC occurrence (odds ratio 1.76, 95% confidence interval 1.06-2.92, P<0.05). HCC rates increased from 13/116 (11.2%; female C/
* carriers), to 97/295 (32.9%; male C/* carriers and female G/G homozygotes), to 31/72 (43.1%; male G/G homozygotes) ( P<0.0001). Conclusions: The PNPLA3 rs738409 C>G polymorphism is associated with cirrhosis. In synergy with gender, this polymorphism is a strong predictor of HCC occurrence among patients with cirrhosis. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
17. Reliability and Reproducibility of the Edmondson Grading of Hepatocellular Carcinoma Using Paired Core Biopsy and Surgical Resection Specimens.
- Author
-
Pirisi, Mario, Leutner, Monica, Pinato, David J., Avellini, Claudio, Carsana, Luca, Toniutto, Pierluigi, Fabris, Carlo, and Boldorini, Renzo
- Subjects
- *
LIVER surgery , *ANALYSIS of variance , *COLLECTION & preservation of biological specimens , *BIOPSY , *COMPUTER software , *HEPATOCELLULAR carcinoma , *RESEARCH methodology , *NURSING assessment , *RESEARCH funding , *STATISTICS , *TUMOR classification , *DATA analysis , *INTER-observer reliability , *REPEATED measures design , *THERAPEUTICS ,RESEARCH evaluation - Abstract
Context.--It has been claimed that the Edmondson and Steiner grading system (EGS) values should be obtained preoperatively to select patients with hepatocellular carcinoma for liver transplantation. However, EGS reliability in biopsy specimens has been questioned. Objective.--To verify the reliability of the EGS using core biopsy specimens and its reproducibility among pathologists. Design.--Paired biopsy and surgical specimens obtained from 40 patients (subset 1) were retrieved by means of computer-aided search of the pathology records and blindly and independently reviewed. The EGS interrater agreement was measured using k statistics. After having held a consensus meeting, pathologists graded an additional 21 paired hepatocellular carcinoma specimens (subset 2). Results.--Analyzing subset 1, pathologists gave significantly lower EGS grades to the biopsy specimens (P , .001), for which the observed agreement was 32.5% (k = 0.021), which increased to 82.5% (k = 0.186) if only 2 categories were considered (low grade, EGS I-II; high grade, EGS III-IV). The observed agreement in the case of the surgical specimens was 52.5% (k = 0.199), which increased to 62.5% (k = 0.275) when the low- and highgrade scores were merged. The observed agreement between the assessments of paired biopsy and surgical specimens was 50.0% for pathologist 1 (k = 0.057) and 35.0% for pathologist 2 (k = 0.078). Merging the EGS grades did not improve the strength of the agreement. Analyzing subset 2 (after the consensus meeting), the observed agreement between pathologists improved more on biopsies (76.2%, k = 0.614) than on surgical specimens (61.9%, k = 0.434). Conclusions.--The EGS is easily underestimated in core biopsy specimens, and interrater disagreement between pathologists can be significant unless consensus meetings are held. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Interleukin-6 Polymorphisms and Gender: Relationship with the Occurrence of Hepatocellular Carcinoma in Patients with End-Stage Liver Disease.
- Author
-
Falleti, Edmondo, Fabris, Carlo, Toniutto, Pierluigi, Fontanini, Elisabetta, Cussigh, Annarosa, Bitetto, Davide, Fumolo, Elisa, Fornasiere, Ezio, Bragagnini, Walter, Pinato, David J., Minisini, Rosalba, and Pirisi, Mario
- Subjects
INTERLEUKIN-6 ,GENETIC polymorphisms ,LIVER cancer ,CIRRHOSIS of the liver ,CANCER patients ,PATIENTS - Abstract
Objective: To investigate whether interleukin-6 (IL-6) polymorphisms could be associated with the occurrence of hepatocellular carcinoma (HCC) in patients with liver cirrhosis and whether this influence could act synergistically with the gender of the patient. Methods: We studied 219 consecutive patients who underwent liver transplantation for liver cirrhosis. All total hepatectomy specimens were sectioned at intervals of 1 cm in search for suspicious focal hepatic lesions. Genotyping for the IL-6 –1363 G>T, –597 G>A, –572 G>C, –174 G>C and +2954 G>C polymorphisms was performed by restriction fragment length polymorphism. Results: A significant association was found between the presence of the A-C/A-C low producer diplotype (–597 G>A/–174 G>C loci) and absence of HCC (18/153 vs. 1/66, p < 0.02). With respect to the IL-6 A-C/A-C low producer phenotype (n = 19), females (n = 60) and males (n = 140) with the high producer phenotypes had an adjusted odds ratio for the presence of HCC of 3.74 and 14.8, respectively (p < 0.001). Conclusions: Polymorphisms of IL-6, by determining differences in its expression, are associated with HCC occurrence among patients with liver cirrhosis. The protective effect of female gender against the occurrence of HCC occurs mainly among carriers of IL-6 high producer phenotypes. Copyright © 2009 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
19. Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma.
- Author
-
Fessas, Petros, Spina, Paolo, Boldorini, Renzo L., Pirisi, Mario, Minisini, Rosalba, Mauri, Francesco A., Simpson, Fraser, Olivieri, Paola, Gennari, Alessandra, Wong, Ching Ngar, Siddique, Abdul, Goldin, Robert D., Akarca, Ayse U., Marafioti, Teresa, Pinato, David J., and Duda, Dan G.
- Subjects
GENETIC mutation ,IMMUNOHISTOCHEMISTRY ,CELL physiology ,FISHER exact test ,MANN Whitney U Test ,CELL receptors ,GENE expression profiling ,DESCRIPTIVE statistics ,CHI-squared test ,T cells ,DATA analysis software ,HEPATOCELLULAR carcinoma ,PHENOTYPES - Abstract
Simple Summary: How liver cancer changes as it progresses from where it initially arises, to metastatic sites distant from the liver, is unclear. We obtained a unique set of paired samples from patients, both from the original site and from metastases. We compared the mutation burden, transcriptional profile, and immune cell infiltrate between primary and secondary samples. We found that liver cancer metastases retain the ability to exclude the immune system from the tumour core as they spread. (1) Background: The intra-tumoural heterogeneity (ITH) of hepatocellular carcinoma (HCC) and its microenvironment (TME) across primary and secondary disease is poorly characterised. (2) Methods: Intra-tumoural (IT) and peri-tumoural (PT) staining of matched primary and secondary samples was conducted to evaluate the distribution of CD4+/FOXP3+ and CD8+/PD1+ T-cells. Samples underwent PD-L1/2 immunostaining, tumour mutational burden (TMB) evaluation, and high-resolution T-cell receptor (TCR) sequencing to derive T-cell clonality and targeted transcriptomics. (3) Results: We analysed 24 samples from matched primary (n = 11) and secondary (n = 13; 5 synchronous, 6 metachronous) deposits, 11 being extrahepatic (84.6%). IT CD8+ density was lower than PT in both primary (p = 0.005) and secondary deposits (p = 0.01), consistent with immune exclusion. PD-L1+ tumours displayed higher IT and PT CD8+/PD1+ cell density compared to PD-L1- (p < 0.05), and primary IT infiltrate was enriched in CD4+/FOXP3+ cells, compared to PT regions (p = 0.004). TCR-sequencing demonstrated enrichment of the top T-cell clonotype in secondary versus primary HCC (p = 0.02), without differences in overall productive clonality (p = 0.35). TMB was similar across primary versus secondary HCC (p = 0.95). While directed gene set analysis demonstrated the uniformity of transcriptional signatures of individual immune cell types, secondary deposits demonstrated higher COLEC12 (p = 0.004), CCL26 (p = 0.02), CD1E (p = 0.02) and CD36 (p = 0.03) expression with downregulation of CXCL1 (p = 0.03), suggesting differential regulation of innate immunity. (4) Conclusion: Immune exclusion is a defining feature of the HCC TME. Despite evidence of homogeneity in somatic TMB, secondary HCC is characterised by the expansion of a distinct T-cell clonotype and differential regulation of innate immune pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease.
- Author
-
Smirne, Carlo, Mulas, Violante, Barbaglia, Matteo Nazzareno, Mallela, Venkata Ramana, Minisini, Rosalba, Barizzone, Nadia, Burlone, Michela Emma, Pirisi, Mario, and Grossini, Elena
- Subjects
FATTY liver ,PERIOSTIN ,HEPATITIS C ,HIGH-calorie diet - Abstract
Circulating periostin has been suggested as a possible biomarker in non-alcoholic fatty liver disease (NAFLD) in Asian studies. In the present study, we aimed to test its still controversial relevance in a Caucasian population. In patients with histologically-proven NAFLD (N. = 74; 10 with hepatocellular carcinoma, HCC) plasma periostin concentrations were analyzed. POSTN haplotype analysis was based on rs9603226, rs3829365, and rs1029728. Hepatitis C patients (N. = 81, 7 HCC) and healthy subjects (N. = 27) were used as controls. The median plasma periostin concentration was 11.6 ng/mL without differences amongst groups; it was not influenced by age, liver fibrosis or steatosis. However, possession of haplotype two (rs9603226 = G, rs3829365 = C, rs1028728 = A) was associated with lower circulating periostin compared to other haplotypes. Moreover, periostin was higher in HCC patients. At multivariate analysis, HCC remained the only predictor of high periostin. In conclusion, plasma periostin concentrations in Caucasians NAFLD patients are not influenced by the degree of liver disease, but are significantly higher in HCC. Genetically-determined differences may account for some of the variability. These data suggest extreme caution in predicting a possible future role of periostin antagonists as a rational therapeutic alternative for NAFLD, but show a potential periostin role in the management of NAFLD-associated HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
- Author
-
Howell, Jessica, Atkinson, Stephen R., Pinato, David J., Knapp, Susanne, Ward, Caroline, Minisini, Rosalba, Burlone, Michela E., Leutner, Monica, Pirisi, Mario, Büttner, Reinhard, Khan, Shahid A., Thursz, Mark, Odenthal, Margarete, and Sharma, Rohini
- Subjects
- *
TUMOR treatment , *LIVER tumors , *CARRIER proteins , *CYTOSKELETAL proteins , *DNA , *EXTRACELLULAR space , *CIRRHOSIS of the liver , *HEPATOCELLULAR carcinoma , *GENETIC mutation , *NUCLEIC acids , *POLYMERASE chain reaction , *SURVIVAL , *TRANSFERASES , *TUMOR markers , *TUMOR classification , *DNA-binding proteins , *TREATMENT effectiveness , *SEQUENCE analysis , *BLOOD , *THERAPEUTICS - Abstract
Hepatocellular carcinoma (HCC) is increasing globally. Prognostic biomarkers are urgently needed to guide treatment and reduce mortality. Tumour-derived circulating cell-free DNA (ctDNA) is a novel, minimally invasive means of determining genetic alterations in cancer. We evaluate the accuracy of ctDNA as a biomarker in HCC. Plasma cell-free DNA, matched germline DNA and HCC tissue DNA were isolated from patients with HCC (n = 51) and liver cirrhosis (n = 10). Targeted, multiplex polymerase chain reaction ultra-deep sequencing was performed using a liver cancer–specific primer panel for genes ARID1A , ARID2 , AXIN1 , ATM , CTNNB1 , HNF1A and TP53. Concordance of mutations in plasma ctDNA and HCC tissue DNA was determined, and associations with clinical outcomes were analysed. Plasma cell-free DNA was detected in all samples. Lower plasma cell-free DNA levels were seen in Barcelona Clinic Liver Cancer (BCLC A compared with BCLC stage B/C/D (median concentration 122.89 ng/mL versus 168.21 ng/mL, p = 0.041). 29 mutations in the eight genes (21 unique mutations) were detected in 18/51 patients (35%), median 1.5 mutations per patient (interquartile range 1–2). Mutations were most frequently detected in ARID1A (11.7%), followed by CTNNB1 (7.8%) and TP53 (7.8%). In patients with matched tissue DNA, all mutations detected in plasma ctDNA detected were confirmed in HCC DNA; however, 71% of patients had mutations identified in HCC tissue DNA that were not detected in matched ctDNA. ctDNA is quantifiable across all HCC stages and allows detection of mutations in key driver genes of hepatic carcinogenesis. This study demonstrates high specificity but low sensitivity of plasma ctDNA for detecting mutations in matched HCC tissue. • Tumour-derived circulating cell-free DNA (ctDNA) can be detected in patients with hepatocellular cancer. • Levels of ctDNA correlate with disease stage, such that levels increased with worsening tumour stage. • Mutations in key known drivers of carcinogenesis were identified in ctDNA. • All mutations in ctDNA were found in matched tumour tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC
- Author
-
Fabris, Carlo, Falleti, Edmondo, Cussigh, Annarosa, Bitetto, Davide, Fontanini, Elisabetta, Bignulin, Sara, Cmet, Sara, Fornasiere, Ezio, Fumolo, Elisa, Fangazio, Stefano, Cerutti, Andrea, Minisini, Rosalba, Pirisi, Mario, and Toniutto, Pierluigi
- Subjects
- *
CIRRHOSIS of the liver , *RESTRICTION fragment length polymorphisms , *HEPATITIS C , *INTERLEUKINS , *LIVER transplantation , *ETIOLOGY of diseases , *PATIENTS - Abstract
Background & Aims: A single nucleotide polymorphism (rs12979860 C/T) 3kb upstream of the interleukin 28B (IL-28B) gene was shown to be associated with hepatitis C clearance. We verified whether this association also translates into a different genotype distribution at the end of the disease trajectory. Methods: A RFLP-PCR technique was used to genotype 412 patients with cirrhosis due to hepatitis C (n =199), hepatitis B (n =75), alcohol (n =110), and other causes (n =28), of whom 256 underwent liver transplantation (OLT). Hepatocellular carcinoma (HCC) was demonstrated in the native liver of 85 OLT patients, 52 with viral cirrhosis, and 33 with non-viral cirrhosis respectively. A group of 292 patients (235 HCV and 57 HBV positive) with mild chronic hepatitis and 344 healthy subjects served as controls. Results: A significant difference (p =0.0005) was observed in IL-28B rs12979860 genotype frequencies between patients with viral cirrhosis (C/C=99, C/T=137, T/T=38) and those with non-viral cirrhosis (C/C=72, C/T=58, T/T=8). Patients with HCV related cirrhosis carried more frequently the T/T genotype in comparison to mild hepatitis C or HBV-related cirrhosis. IL-28B rs12979860 genotype frequencies were C/C=23, C/T=50, T/T=12 among OLT patients with cirrhosis complicated by HCC, and C/C=79, C/T=78, T/T=14 among patients with cirrhosis not complicated by HCC (p <0.005). Conclusions: IL-28B rs12979860 C/T polymorphism T allele is more prevalent in patients with viral cirrhosis due to HCV in comparison to other aetiologies and to patients with mild chronic hepatitis C. Among OLT patients, carriage of this allele seems to augment the risk of developing HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
23. TGF-β1 genotypes in cirrhosis: Relationship with the occurrence of liver cancer
- Author
-
Falleti, Edmondo, Fabris, Carlo, Toniutto, Pierluigi, Fontanini, Elisabetta, Cussigh, Annarosa, Bitetto, Davide, Fornasiere, Ezio, Avellini, Claudio, Minisini, Rosalba, and Pirisi, Mario
- Subjects
- *
TRANSFORMING growth factors-beta , *CIRRHOSIS of the liver , *NUCLEOTIDE sequence , *LIVER cancer , *BLOOD donors , *LIVER transplantation , *VIRAL hepatitis - Abstract
Abstract: This study aimed to verify whether specific single nucleotide polymorphisms (SNPs) of the transforming growth factor-β1 (TGF-β1) may predispose to end-stage liver disease and/or hepatocellular carcinoma (HCC). One hundred eighty-eight consecutive patients transplanted for liver cirrhosis (HBV N =21, HCV N =68, alcoholic N =55 and others N =23) and a control group of 140 healthy blood donors were investigated. Four SNPs were studied by restriction fragment length assays: −800G>A, −509C>T, Leu10Pro and Arg25Pro. Patients were found to possess the −509T/∗ (TT 53/188, CT 85/188, CC 50/188 vs TT 22/140, CT 61/140, CC 57/140; p <0.002) and Arg25Pro C/∗ genotypes (CC 1/188, CG 31/188, GG 156/188 vs CC 0/140, CG 13/140, GG 127/140; p <0.05) more frequently than controls. Patients with cirrhosis complicated by HCC possessed more frequently the Leu10Pro T/∗ genotype than patients without HCC (TT 20/54, CT 26/54, CC 8/54 vs TT 31/134, CT 69/134, CC 34/134; p <0.05). The analysis of molecular variance detected significant genotypic differentiations between controls and cirrhotics but not between cirrhotics with or without HCC. In conclusion, TGF-β1 SNPs probably facilitate the development of liver cirrhosis, while they seem to have a limited role in predicting the occurrence of HCC. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
24. FRI493 - Interplay of PNPLA and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients.
- Author
-
De Benedittis, Carla, Crevola, Martina, Mallela, Venkata Ramana, Barbaglia, Matteo Nazzareno, Fangazio, Stefano, Elisa, Ceriani, Bellan, Mattia, Rigamonti, Cristina, Minisini, Rosalba, and Pirisi, Mario
- Subjects
- *
HEPATITIS C virus , *HEPATOCELLULAR carcinoma - Published
- 2020
- Full Text
- View/download PDF
25. Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis
- Author
-
Tommaso Stroffolini, Evangelista Sagnelli, Angelo Andriulli, Guido Colloredo, Caterina Furlan, Giovanni Battista Gaeta, Filomena Morisco, Mario Pirisi, Floriano Rosina, Caterina Sagnelli, Antonina Smedile, Piero Luigi Almasio, EPACRON study group, Stroffolini, Tommaso, Sagnelli, Evangelista, Andriulli, Angelo, Colloredo, Guido, Furlan, Caterina, Gaeta, Giovanni Battista, Morisco, Filomena, Pirisi, Mario, Rosina, Floriano, Sagnelli, Caterina, Smedile, Antonina, Almasio, Piero Luigi, Stroffolini T., Sagnelli E., Andriulli A., Colloredo G., Furlan C., Gaeta G.B., Morisco F., Pirisi M., Rosina F., Sagnelli C., Smedile A., and Almasio P.L.
- Subjects
Genetics and Molecular Biology (all) ,0301 basic medicine ,Liver Cirrhosis ,RNA viruses ,Male ,Chronic Hepatitis ,Cirrhosis ,lcsh:Medicine ,Alcohol abuse ,Hepacivirus ,Sex Factor ,Chronic liver disease ,medicine.disease_cause ,Biochemistry ,Gastroenterology ,Chronic Liver Disease ,0302 clinical medicine ,Risk Factors ,Medicine and Health Sciences ,lcsh:Science ,Pathology and laboratory medicine ,Multidisciplinary ,Alcohol Consumption ,Hepatitis C virus ,Liver Diseases ,Fatty liver ,virus diseases ,Hepatitis C ,Hepatitis B ,Medical microbiology ,Middle Aged ,Oncology ,Viruses ,Coinfection ,030211 gastroenterology & hepatology ,Female ,Pathogens ,Research Article ,Human ,Adult ,medicine.medical_specialty ,Hepatitis B virus ,Alcohol Drinking ,Liver Cirrhosi ,Gastroenterology and Hepatology ,Microbiology ,Carcinomas ,03 medical and health sciences ,Sex Factors ,Internal medicine ,Gastrointestinal Tumors ,medicine ,Humans ,Nutrition ,Aged ,Biochemistry, Genetics and Molecular Biology (all) ,Flaviviruses ,business.industry ,Risk Factor ,lcsh:R ,Organisms ,Viral pathogens ,Biology and Life Sciences ,Cancers and Neoplasms ,Hepatocellular Carcinoma ,medicine.disease ,Virology ,digestive system diseases ,Hepatitis viruses ,Agricultural and Biological Sciences (all) ,Diet ,Microbial pathogens ,Fatty Liver ,030104 developmental biology ,lcsh:Q ,business - Abstract
Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysis. Results Females were older than males (p
- Published
- 2017
26. Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology
- Author
-
Tommaso Stroffolini, Evangelista Sagnelli, Giovanni Battista Gaeta, Caterina Sagnelli, Angelo Andriulli, Giuseppina Brancaccio, Mario Pirisi, Guido Colloredo, Filomena Morisco, Caterina Furlan, Piero Luigi Almasio, Sergio Babudieri, Bruno Cacopardo, Nicola Coppola, Massimo De Luca, Anna Licata, Mariantonietta Pisaturo, Floriano Rosina, Maurizio Russello, Teresa Santantonio, Antonina Smedile, Stroffolini, T., Sagnelli, E., Gaeta, G., Sagnelli, C., Andriulli, A., Brancaccio, G., Pirisi, M., Colloredo, G., Morisco, F., Furlan, C., Almasio, P., Babudieri, S., Cacopardo, B., Coppola, N., De Luca, M., Licata, A., Pisaturo, M., Rosina, F., Russello, M., Santantonio, T., Smedile, A., Stroffolini, Tommaso, Sagnelli, Evangelista, Gaeta, Giovanni Battista, Sagnelli, Caterina, Andriulli, Angelo, Brancaccio, Giuseppina, Pirisi, Mario, Colloredo, Guido, Morisco, Filomena, Furlan, Caterina, Almasio, Piero Luigi, Babudieri, S, Cacopardo, B, Coppola, N, De Luca, M, Licata, A, Pisaturo, M, Rosina, F, Russello, M, and Santantonio, T
- Subjects
Male ,Cirrhosis ,Settore MED/09 - Medicina Interna ,Alcohol abuse ,HBV ,HCV ,Liver cirrhosis ,Liver cirrhosis epidemiology ,Internal Medicine ,medicine.disease_cause ,Gastroenterology ,0302 clinical medicine ,Risk Factors ,Epidemiology ,030212 general & internal medicine ,Liver Neoplasms ,virus diseases ,Middle Aged ,Hepatitis B ,Hepatitis C ,Alcoholism ,Italy ,Liver Neoplasm ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Aged ,Carcinoma, Hepatocellular ,Cross-Sectional Studies ,Female ,Humans ,Liver Cirrhosis ,Human ,medicine.medical_specialty ,Hepatitis C virus ,Liver Cirrhosi ,03 medical and health sciences ,Internal medicine ,medicine ,Decompensation ,Hepatitis B virus ,Cross-Sectional Studie ,business.industry ,Risk Factor ,Carcinoma ,Hepatocellular ,medicine.disease ,Etiology ,business - Abstract
Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child A cirrhosis and 17.9% superimposed hepatocellular carcinoma. HCV infection, alone or in combination with other aetiologic agents, was responsible of 58.6% of cases, HBV aetiology accounted for the 17.6% and alcohol abuse for the 16.0%. Compared with virus-related cirrhotic patients, those alcohol-related more frequently showed decompensation (p=0.02). CONCLUSIONS: Compared to previous surveys performed in 1992 and in 2001, we observe a statistically significant (p
- Published
- 2016
27. PS-113-Analysis of the HSD17B13: TA allelic variant as a putative protective factor towards hepatocellular carcinoma in patients with and without chronic hepatitis C.
- Author
-
Fazio, Martina, Benedittis, Carla De, Burlone, Michela Emma, Barbaglia, Matteo Nazzareno, Venkata, Ramana Mallela, Panero, Antonio, Minisini, Rosalba, and Pirisi, Mario
- Subjects
- *
FATTY liver , *HEPATITIS C , *CHRONIC hepatitis C , *HEPATOCELLULAR carcinoma , *RESTRICTION fragment length polymorphisms - Published
- 2019
- Full Text
- View/download PDF
28. FRI-503-Sorafenib starting dose impacts on survival in the elderly population with hepatocellular cancer.
- Author
-
Hajiev, Saur, Pinato, David J, Ramaswami, Ramya, Black, James M, arizumi, t, Pirisi, Mario, kudo, m, and sharma, rohini
- Subjects
- *
LIVER cancer , *OLDER patients , *HEPATOCELLULAR carcinoma , *SORAFENIB , *DRUG dosage , *SURVIVAL analysis (Biometry) , *DRUG toxicity - Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.